Literature DB >> 23197779

Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns.

Rony Atoui1, Ray C J Chiu.   

Abstract

Stem cell transplantation is a promising approach for improving cardiac function after severe myocardial damage, for which the use of autologous donor cells has been preferred to avoid immune rejection. Recently, however, rodent as well as human mesenchymal stem cells have been reported to be uniquely immune-tolerant, in both in vitro and in vivo transplant models. In this review, we explore in detail the current understanding of the underlying immunologic mechanisms, which can facilitate the use of such cells as "universal donor cells" with fascinating clinical implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23197779      PMCID: PMC3659851          DOI: 10.5966/sctm.2011-0012

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  47 in total

1.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Authors:  Ida Rasmusson; Olle Ringdén; Berit Sundberg; Katarina Le Blanc
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

Review 2.  Mesenchymal stem cells: paradoxes of passaging.

Authors:  Elisabeth H Javazon; Kirstin J Beggs; Alan W Flake
Journal:  Exp Hematol       Date:  2004-05       Impact factor: 3.084

Review 3.  "Stealth immune tolerance" in stem cell transplantation: potential for "universal donors" in myocardial regenerative therapy.

Authors:  Ray C J Chiu
Journal:  J Heart Lung Transplant       Date:  2005-05       Impact factor: 10.247

4.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

5.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

6.  Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

Authors:  Alma J Nauta; Geert Westerhuis; Alwine B Kruisselbrink; Ellie G A Lurvink; Roel Willemze; Willem E Fibbe
Journal:  Blood       Date:  2006-05-11       Impact factor: 22.113

7.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

8.  Human mesenchymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel.

Authors:  Karl-Henrik Grinnemo; Agneta Månsson-Broberg; Katarina Leblanc; Matthias Corbascio; Eva Wärdell; Anwar J Siddiqui; Xiaojin Hao; Christer Sylvén; Göran Dellgren
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

9.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

Authors:  Katarina Le Blanc; Charlotte Tammik; Kerstin Rosendahl; Eva Zetterberg; Olle Ringdén
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

10.  Marrow stromal cells as universal donor cells for myocardial regenerative therapy: their unique immune tolerance.

Authors:  Rony Atoui; Juan-Francisco Asenjo; Minh Duong; Guangyong Chen; Ray C-J Chiu; Dominique Shum-Tim
Journal:  Ann Thorac Surg       Date:  2008-02       Impact factor: 4.330

View more
  25 in total

1.  Hypoxic Conditioned Medium From Human Adipose-Derived Stem Cells Promotes Mouse Liver Regeneration Through JAK/STAT3 Signaling.

Authors:  Sang Chul Lee; Hye Jin Jeong; Sang Kuon Lee; Say-June Kim
Journal:  Stem Cells Transl Med       Date:  2016-04-21       Impact factor: 6.940

2.  Dental pulp stem cells suppress the proliferation of lymphocytes via transforming growth factor-β1.

Authors:  Gang Ding; Jianyi Niu; Yi Liu
Journal:  Hum Cell       Date:  2015-01-21       Impact factor: 4.174

Review 3.  Current understanding of the immunosuppressive properties of mesenchymal stromal cells.

Authors:  Ligia Lins de Castro; Miquéias Lopes-Pacheco; Daniel Jay Weiss; Fernanda Ferreira Cruz; Patricia Rieken Macêdo Rocco
Journal:  J Mol Med (Berl)       Date:  2019-03-22       Impact factor: 4.599

4.  Rethinking clinical delivery of adult stem cell therapies.

Authors:  Nuala Trainor; Alexis Pietak; Tim Smith
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

Review 5.  Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases.

Authors:  Vidul Goenka; Tanhai Borkar; Aska Desai; Raunak Kumar Das
Journal:  J Diabetes Metab Disord       Date:  2020-10-17

6.  Synthetic MSC? Nothing Beats the Real Thing.

Authors:  Megan M Monsanto; Bingyan J Wang; Mark A Sussman
Journal:  Circ Res       Date:  2017-05-26       Impact factor: 17.367

7.  Addition of autologous mesenchymal stem cells to whole blood for bioenhanced ACL repair has no benefit in the porcine model.

Authors:  Benedikt L Proffen; Patrick Vavken; Carla M Haslauer; Braden C Fleming; Chad E Harris; Jason T Machan; Martha M Murray
Journal:  Am J Sports Med       Date:  2014-12-30       Impact factor: 6.202

Review 8.  Mesenchymal stem cells in treating autism: Novel insights.

Authors:  Dario Siniscalco; James Jeffrey Bradstreet; Nataliia Sych; Nicola Antonucci
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

9.  Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models.

Authors:  Linda N Liu; Gang Wang; Kyle Hendricks; Keunmyoung Lee; Ernst Bohnlein; Uwe Junker; Joseph D Mosca
Journal:  Stem Cells Transl Med       Date:  2013-04-16       Impact factor: 6.940

10.  Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.

Authors:  Lorena R Braid; Wei-Gang Hu; John E Davies; Les P Nagata
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.